We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




CD Diagnostics Acquires CLIA-Accredited Citrano Medical Laboratories

By LabMedica International staff writers
Posted on 30 Oct 2012
CD Diagnostics, Inc. More...
(Wynnewood, PA, USA) completed the purchase of 80% of the outstanding capital stock of Citrano Medical Laboratories, Inc. (CML; Towson, MD, USA).

CML provides clinical laboratory testing to physicians, clinics, and long-term care facilities. The combination of Citrano with CD Diagnostics creates an entity with both a strong R and D team that can produce Laboratory Developed Tests (LDTs), and a Clinical Laboratory Improvement Amendments (CLIA)-certified diagnostics laboratory dedicated to customer service in which these tests can be run.

CD Diagnostics' immunoassays use a small sample of a patient’s joint fluid (synovial fluid) to measure the presence of proteins or biomarkers that are produced by the body and are specific to a particular joint disease. The presence of these biomarkers in elevated levels indicates that the patient is reacting to a specific joint disease and serves as a positive diagnosis. Results are accurate and available within five to ten minutes. The first test, an immunoassay to diagnose infection in joint replacements, is planned for release in November 2012. Joint infection is a very serious condition that must be ruled out with any joint disease.

The first test, CD Diagnostics’ new synovial fluid assays will enhance Citrano’s portfolio of testing services, which currently include hematology, urinalysis, and a broad range of other services.

The acquisition of Citrano is one of the milestones achieved by CD Diagnostics since its incorporation in December 2011. In June 2012, the company signed a commercialization agreement with an orthopedic company for the development of its infection test, receiving USD 2.9 million in milestone payments.

Richard Birkmeyer, CEO of CD Diagnostics, commented, “When you have inflammation in a joint, it can be a wide range of causes such as Lyme disease, gout, bacterial infection. Our test tells exactly what is causing that pain, no matter what the joint.” Tests for other joint diseases are in development.

Related Links:

CD Diagnostics, Inc.
Citrano Medical Laboratories, Inc.



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Automatic Western Blot Analyzer
Tenfly Phoenix Blot Analyzer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.